Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
135.44
-2.87 (-2.08%)
At close: Jul 22, 2026, 4:00 PM EDT
135.44
0.00 (0.00%)
Pre-market: Jul 23, 2026, 7:25 AM EDT
Protagonist Therapeutics Revenue
Protagonist Therapeutics had revenue of $56.37M in the quarter ending March 31, 2026, with 99.03% growth. This brings the company's revenue in the last twelve months to $74.06M, down -64.36% year-over-year. In the year 2025, Protagonist Therapeutics had annual revenue of $46.02M, down -89.41%.
Revenue (ttm)
$74.06M
Revenue Growth
-64.36%
P/S Ratio
117.61
Revenue / Employee
$565,366
Employees
131
Market Cap
8.71B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 46.02M | -388.42M | -89.41% |
| Dec 31, 2024 | 434.43M | 374.43M | 624.06% |
| Dec 31, 2023 | 60.00M | 33.42M | 125.73% |
| Dec 31, 2022 | 26.58M | -776.00K | -2.84% |
| Dec 31, 2021 | 27.36M | -1.27M | -4.44% |
| Dec 31, 2020 | 28.63M | 28.40M | 12,293.07% |
| Dec 31, 2019 | 231.00K | -30.69M | -99.25% |
| Dec 31, 2018 | 30.93M | 10.86M | 54.14% |
| Dec 31, 2017 | 20.06M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Halozyme Therapeutics | 1.51B |
| Ionis Pharmaceuticals | 1.06B |
| Corcept Therapeutics | 769.10M |
| Krystal Biotech | 417.30M |
| Kymera Therapeutics | 51.48M |
| Crinetics Pharmaceuticals | 18.07M |
| Praxis Precision Medicines | 7.46M |
PTGX News
- 6 days ago - Protagonist Therapeutics price target raised to $165 from $137 at Citizens - TheFly
- 6 days ago - Protagonist Therapeutics Reports Granting of Inducement Awards - Accesswire
- 9 days ago - Protagonist Therapeutics price target raised to $151 from $119 at Barclays - TheFly
- 15 days ago - Protagonist Therapeutics price target raised to $145 from $121 at Truist - TheFly
- 5 weeks ago - Protagonist Therapeutics Transcript: AGM 2026 - Transcripts
- 6 weeks ago - Protagonist Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Protagonist Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress - Accesswire